ClinicalTrials.gg
Not yet recruitingNCT07700043Updated Jul 13, 2026

Noise Reduction With Hearing Aids

An interventional study of Speech Enhancement using Decomposition Approach-Hearing Aid (SEDA-HA) algorithm and Hearing aid (HA) prototype with SEDA-HA algorithm in Bilateral Sensorineural Hearing Loss, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hearing Loss by NYU Langone Health — 6 open to participants now, 6 under way, none of them phase 3. Hearing Loss · NYU Langone Health.

Planned enrollment
Largest of 10
60 · median 14
Started
2026
the only one that year
No phase
10 of 10
6 open now
Registered
10th of 10
by date

Among the 10 studies in Hearing Loss by NYU Langone Health, this one has the largest planned enrollment, is the only one that started in 2026, is one of 10 with no phase, and was the 10th registered.

Hearing Loss

797 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.

Browse Hearing Loss studies →

Open to participants now

6 of the 10 studies in Hearing Loss by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hearing Loss by NYU Langone Health, or all of them as a file.
02

Study summary

The purpose of this study is to use an optimized version of the SEDA algorithm (SEDA-HA) for hearing aids to evaluate the benefit for listeners with varying degrees of hearing loss in realistic environments and evaluate its impact on speech perception and sound quality. The primary objective is to evaluate performance with and without the SEDA-HA algorithm on speech perception and speech reception tasks. The secondary objective is to evaluate performance of and experience with SEDA-HA integrated into a portable hearing aid prototype in the laboratory and in real-world situations outside the laboratory.

03

Conditions studied

  • Bilateral Sensorineural Hearing Loss

Browse trials for

Keywords

  • Hearing aid
  • Hearing loss
  • Cochlear Implant
  • CI
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 16 years of age and older
  • Bilateral sensorineural hearing loss. Hearing loss will be diagnosed as sensorineural by an air-bone gap of no more than 10 dB averaged across 0.5, 1, 2, and 3 kHz and Type A tympanograms.
  • Mild, moderate, or severe hearing loss. Hearing loss classification will be dependent on 4-frequency pure tone average (PTA, 0.5, 1, 2 and 4kHz) in the test ear. The mild group will have a PTA of 25-40 dB HL; moderate group will have a PTA of 41-60 dB HL; the severe group will have a PTA of 61-90 dB HL.
  • Be willing and able to provide consent.

Exclusion criteria

Exclusion Criteria:

  • under 16 years of age
  • Participants with conductive or mixed hearing loss (i.e. have more than a 10 dB air-bone gap averaged across 0.5, 1, 2, and 3 kHz or tympanograms other than Type A)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Mild hearing loss

    Speech reception and speech perception will be measured in the presence of various types of background noise with and without the use of the SEDA-HA algorithm. Only participants ages 18 and older in this group will have the option to evaluate SEDA-HA integrated into a portable hearing aid prototype in a take-home trial.

    Device: Speech Enhancement using Decomposition Approach-Hearing Aid (SEDA-HA) algorithm · Device: Hearing aid (HA) prototype with SEDA-HA algorithm

  • Experimental
    Moderate hearing loss

    Speech reception and speech perception will be measured in the presence of various types of background noise with and without the use of the SEDA-HA algorithm. Only participants ages 18 and older in this group will have the option to evaluate SEDA-HA integrated into a portable hearing aid prototype in a take-home trial.

    Device: Speech Enhancement using Decomposition Approach-Hearing Aid (SEDA-HA) algorithm · Device: Hearing aid (HA) prototype with SEDA-HA algorithm

  • Experimental
    Severe hearing loss

    Speech reception and speech perception will be measured in the presence of various types of background noise with and without the use of the SEDA-HA algorithm. Only participants ages 18 and older in this group will have the option to evaluate SEDA-HA integrated into a portable hearing aid prototype in a take-home trial.

    Device: Speech Enhancement using Decomposition Approach-Hearing Aid (SEDA-HA) algorithm · Device: Hearing aid (HA) prototype with SEDA-HA algorithm

Interventions

  • DeviceSpeech Enhancement using Decomposition Approach-Hearing Aid (SEDA-HA) algorithm

    All participants will complete the testing using the SEDA-HA algorithm.

  • DeviceHearing aid (HA) prototype with SEDA-HA algorithm

    The study device is a non-invasive, acoustic hearing aid prototype developed by York Sound. Participants ages 18 and older will then take-home the HA prototype to begin the at home protocol for 30 days.

06

What researchers measure

Primary outcomes

  1. Number of words repeated with SEDA

    Participant will listen to an IEEE (IEEE Subcommittee, 1969) sentence and repeat all the words they hear. The process will be repeated for 10 sentences in each listening condition. Background noise will consist of one of five noise types (Babble, White Gaussian, Speech-Shaped, Restaurant, and Traffic) and one of five SNRs (-4, -2, 0, 3, and 6 dB). Each listening condition will be evaluated with and without SEDA, in an order that is randomized across participants.

    Time frame: Day 1 (up to 4 hours)

  2. Number of words repeated without SEDA

    Participant will listen to an IEEE (IEEE Subcommittee, 1969) sentence and repeat all the words they hear. The process will be repeated for 10 sentences in each listening condition. Background noise will consist of one of five noise types (Babble, White Gaussian, Speech-Shaped, Restaurant, and Traffic) and one of five SNRs (-4, -2, 0, 3, and 6 dB). Each listening condition will be evaluated with and without SEDA, in an order that is randomized across participants.

    Time frame: Day 1 (up to 4 hours)

  3. Number of participants who preferred SEDA-on condition

    The hearing aid prototype will feature two buttons "P1" and "P2", which correspond to the SEDA-on and SEDA-off conditions. Subjects will be asked if they prefer "P1" or "P2".

    Time frame: Day 30

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: David.Landsberger@nyulangone.org . The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to David.Landsberger@nyulangone.org To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

Of 197 non-industry interventional studies with no phase under Hearing Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 59. This study's planned 36 months is above that.

Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07700043
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

Natalia Stupak
Contact
Natalia.stupak@nyulangone.org
646-501-4153
David Landsberger, Ph.D.
Contact
David.landsberger@nyulangone.org
David Landsberger, Ph.D.
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion